- Research article
- Open Access
Optimization of expression conditions for a novel NZ2114-derived antimicrobial peptide-MP1102 under the control of the GAP promoter in Pichia pastoris X-33
BMC Microbiology volume 15, Article number: 57 (2015)
The infections caused by antibiotic multidrug-resistant bacteria seriously threaten human health. To prevent and cure the infections caused by multidrug-resistant bacteria, new antimicrobial agents are required. Antimicrobial peptides are ideal therapy candidates for antibiotic-resistant pathogens. However, due to high production costs, novel methods of large-scale production are urgently needed.
The novel plectasin-derived antimicrobial peptide-MP1102 gene was constitutively expressed under the control of the GAP promoter. The optimum carbon source and concentration were determined, and 4% glucose (w/v) was initially selected as the best carbon source. Six media were assayed for the improved yield of recombinant MP1102 (rMP1102). The total protein and rMP1102 yield was 100.06 mg/l and 42.83 mg/l, which was accomplished via the use of medium number 1. The peptone and yeast extract from Hongrun Baoshun (HRBS, crude industrial grade, Beijing, China) more effectively improved the total protein and the yield of rMP1102 to 280.41 mg/l and 120.57 mg/l compared to 190.26 mg/l and 78.01 mg/l that resulted from Oxoid (used in the research). Furthermore, we observed that the total protein, antimicrobial activity and rMP1102 yield from the fermentation supernatant increased from 807.42 mg/l, 384,000 AU/ml, and 367.59 mg/l, respectively, in pH5.0 to 1213.64 mg/l, 153,600 AU/ml and 538.17 mg/ml, respectively in pH 6.5 in a 5-l fermenter. Accordingly, the productivity increased from 104464 AU/mg rMP1102 in pH 5.0 to a maximum of 285412 AU/mg rMP1102 in pH 6.5. Finally, the recombinant MP1102 was purified with a cation-exchange column with a yield of 376.89 mg/l, 96.8% purity, and a molecular weight of 4382.9 Da, which was consistent with its theoretical value of 4383 Da.
It’s the highest level of antimicrobial peptides expressed in Pichia pastoris using GAP promoter so far. These results provide an economical method for the high-level production of rMP1102 under the control of the GAP promoter.
Antimicrobial peptides (AMPs) are widely distributed host defense molecules that are produced by certain single-cell organisms, including prokaryotic and eukaryotic organisms, as well as all multicellular plants and animals . Plectasin is a recently reported novel defensin-like AMP from Pseudoplectania nigrella that has potent antimicrobial activity against gram-positive pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae and S. suis, including some antibiotic-resistant strains [2,3]. Similar to vancomycin, plectasin binds to the pyrophosphate moiety of lipid II and subsequently prevents the formation of the bacterial cell wall, which inhibits colonization of the pathogens . NZ2114 is a novel variant of plectasin that has significantly more potent activities than its parental peptide plectasin [5,6]. NZ2114 is active against various strains of S. pneumoniae and S. aureus in vitro and in vivo [5,7,8]. To further improve its antibacterial activity and physical and chemical properties, a new sequence named MP1102 was designed which had three mutational sites (N9E, L13V, R14K) compared to NZ2114 in our laboratory. The minimal inhibitory concentrations (MICs) of MP1102 for S. aureus ATCC25923, ATCC29213 and ATCC43300 were 0.021, 0.06 and 0.06 μM, respectively, and these values were equal to or more potent than those of its parental peptide NZ2114, which are 0.028, 0.11 and 0.9 μM, respectively.
The methylotrophic yeast Pichia pastoris has been successfully used as a host system for the expression of heterologous proteins. The high-level expression of heterologous protein by P. pastoris has typically been achieved using a pAOX1 expression system. However, this system is inconvenient during fermentation due to tedious processing and can create environmental pollution or fires during transportation. A constitutive glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter was used as an alternative to the AOX promoter (Waterham et al. ). GAP is essential in carbohydrate metabolism; thus the target proteins of this promoter are expressed during the growth of the host. Consequently, cultivation is simplified because methanol is not needed as a carbon source. It gave comparable expression levels to the AOX1 promoter for some proteins, including β-Lactamase , xylanase , and human granulocyte-macrophage colony stimulating factor [11,12]. However, the operations manual of GAP promoter in P. pastoris indicated that toxic target proteins to the Pichia cell cannot be expressed with high yields (Invitrogen, Manual part no: 25–0174). Consequently, only LL37 (intracellular expression, no exact yield), human α-defensin 5 (1 mg/l) and cecropin D (485 mg/l) have been expressed with the GAP promoter [13-15]. NZ2114 is a peptide that has low toxicity to host cells and is produced at high levels in P. pastoris expression systems . MP1102 is an NZ2114-derived antimicrobial peptide without toxicity to P. pastoris that has been expressed behind the AOX promoter to produce a yield of 695 mg/l (accepted by Appl Microbiol Biotechnol, DOI 10.1007/s00253-015-6394-7), which is lower than the production of NZ2114 (2,390 mg/l). The GAP promoter was used as an alternative to the AOX promoter in this study.
In the P. pastoris expression system using the GAP promoter, the carbon source is the key element for heterologous protein expression . Additionally, the medium is another key factor for the high-level expression of heterologous protein. Various types of basal salts media (BSM) are widely used at the fermenter level in P. pastoris expression systems. However, the definite and limited nutrients of BSM are not suitable for the large-scale production of all proteins. An effective and cheap industrial medium is urgently needed for the industrial production of MP1102.
In the present study, the recombinant plasmid pGAPMP1102 was constructed and transformed into P. pastoris X-33. The optimum carbon source and its concentration were determined. Additionally, the effects of Oxoid and HRBS yeast extracts and peptones (crude industrial grades) were compared, and the effects of five different pH values were evaluated in a 5-l fermenter using fed-batch fermentation. The recombinant MP1102 (rMP1102) was purified with a cation-exchange column and confirmed by matrixassisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS).
Vector construction and screening of positive transformant
As shown in Figure 1, the pGAPMP1102 plasmid contained an inserted target MP1102 fragment of 120 bp. All positive transformants were verified by sequencing. The correct pGAPMP1102 recombinant plasmid was linearized with AvrII and transformed into P. pastoris X-33 by electroporation. The positive transformants were screened by PCR using GAP gene-specific and MP1102 gene-specific primers, and an empty pPICZαA vector transformant was used as the negative control (data not shown).
Confirmation of the anti-S. aureus activity of the transformant and carbon source screening
Thirty positive transformants were used for fermentation in shake flasks. All transformants exhibited some level of antimicrobial activity (Figure 2A). A predominant band between 3.3 and 5.8 kDa was observed in lanes 1–7, the total protein and rMP1102 yield of up to 43.6 mg/l and 18.31 mg/l were observed after 72 h of cultivation (Figure 2B).
Unlike the AOX1 promoter, which is inactive on glucose and glycerol and requires methanol to initiate target gene expression, the GAP promoter constitutively expresses target proteins on different carbon sources . The yield of rMP1102 increased with increasing carbon source concentrations until 40 g/l. The maximum total protein level, rMP1102 yield and antimicrobial activity were 67.8 mg/l, 27.8 mg/l and 6400 AU/ml, respectively, after 96 h of cultivation at an initial glucose concentration of 40 g/l (Figure 3A, B). Additionally, rMP1102 was not secreted into the medium at high levels when low concentrations (10 and 20 g/l) of any of the three carbon sources were used. However, the yields of rMP1102 decreased to 26.16 and 18.71 mg/l in glucose and maltose, respectively at concentrations of 50 g/l (P < 0.05), which suggested that excessive high carbon source concentrations did not benefit the production of rMP1102.
Medium selection for the high-level production of rMP1102
To identify the best medium for the high-level production of rMP1102, six different media were examined. As shown in Figure 3C, the highest total protein and rMP1102 yield of 100.06 mg/l and 42.83 mg/l were observed with Med-1 following 120 h of cultivation. To further improve this yield and identify a suitable medium for rMP1102 production, yeast extracts and peptones from Oxoid and HRBS (crude industrial grades) were added. The higher total protein, rMP1102 yield and antimicrobial activity of 280.41 mg/l, 120.57 mg/l and 12800 AU/ml were observed following the addition of industrial yeast extract and peptone to Med-1 (Figure 4A, B); this yield was 2.80 times that observed with Med-1 alone. Additionally, the total protein, rMP1102 yield and antimicrobial activity were 190.26 mg/l, 78.01 mg/l and 9600 AU/ml following the use of Med-1 with added Oxoid yeast extract and peptone (Figure 4A, B). Tricine-SDS–PAGE revealed a target band of rMP1102 between 4.4 and 10.0 kDa that was more obvious following the use of Med-1 with HRBS yeast extract and peptone than the medium that contained Oxoid (Figure 4C, D), which suggesting that industrial yeast extract and peptone were more suitable for the production of rMP1102.
Development of fed-batch cultivation in bioreactors
The experiments involving the fermentation of rMP1102 in 5-l fermenters focused on pH because pH is the key factor that influences the yields of target proteins . The total protein level, rMP1102 yield and antimicrobial activity of the fermentation supernatant increased from 807.42 mg/l, 367.59 mg/l and 38,400 AU/ml, respectively, at pH 5.0 to the maximum values of 1213.64 mg/l, 538.17 mg/l and 153,600 AU/ml, respectively, at pH6.5 (Table 1). However, the corresponding values decreased to 1127.38 mg/l, 503.92 mg/l and 102,400 AU/ml at pH 7.0, which was not the perfect condition for the growth of the host and target peptide production in P. pastoris. This pattern of productivity paralleled the absolute antimicrobial activity values. The lowest productivity was 104464 AU/mg rMP1102, which was observed at the pH of 5.0, and the maximum max value occurred in pH 6.5 and was 285412 AU/mg rMP1102. However, productivity did not increase when the pH was raised to 7.0 (Table 1). Moreover, a wider target band resulted from pH 6.5 compared to the other pH values (Figure 5A, C, E, G, I). Additionally, the cell wet weights and total protein levels increased with the process of cultivation in all pH values (Figure 5B, D, F, H, J). The total protein level increased to the maximums at 84 and 96 h in the pHs of 5.0, 5.5, and 6.0. However, the highest total protein level and antimicrobial activity occurred at 120 h at the pHs of 6.5 and 7.0, which suggested that these conditions were beneficial for the continuous accumulation of rMP1102, whereas the target peptides accumulated faster in the low 5.0, 5.5, and 6.0 pH conditions (Figure 5B, D, F, H, J). rMP1102 was also expressed in P. pastoris via the inducible method at the 5-l fermenter level. The maximum total protein level was 695 mg/l at 120 h (accepted by Appl Microbiol Biotechnol, DOI 10.1007/s00253-015-6394-7), which was more than 70% reduced compared to the constitutive expression at pH 6.5. Furthermore, another non-target band appeared above rMP1102 between 3.3 and 5.8 kDa. This band might have represented incomplete cleavage by Kex2 due to the large amount of target peptides that were induced by methanol in a short time . In contrast, there only the target rMP1102 was expressed in each of the assays that used the GAP promoter (Figure 5A, C, E, G, I). Very few or no other bands appeared around rMP1102, which was convenient for the process of purification.
Purification and identification of rMP1102
rMP1102 was purified from the culture supernatant using a two-step purification protocol in a 5-l fermenter using Med-1 supplemented with industrial yeast extract and peptone at pH 6.5. As shown in Table 2, after the two-step purification, a total of 1.273 × 108 AU and 376.89 mg of protein was obtained from 1000 ml of culture supernatant (Table 2). The final recovery yield, based on total activity, was 82.9%. A single band of rMP1102 from the purified sample was observed and exhibited a purity of 96.8% (Figure 6A). The results of MALDI-TOF MS of the purified rMP1102 indicated that the molecular weight of the target band was 4382.9 Da, which is consistent with its theoretical value of 4383 Da (Figure 6B).
The main hosts used for AMP production are bacteria and yeasts, which are used to produce 97.4% of the heterologously expressed AMPs . Due to the mechanisms of membrane disruption and cell wall compound blocking, which induce death [4,22], very low yields of target peptides are obtained by directly expressing AMPs in prokaryotic expression systems. Therefore, fusion partners, such as thioredoxin (Trx), glutathione-S-transferase (GST) and small ubiquitin-related modifier (SUMO), have been introduced to avoid host toxicity [23-25]. However, it is quite difficult to recover large fusion proteins at reasonable ratios, so this process is uneconomical and laborious. P. pastoris is a high-yield host for the antimicrobial peptide production and has some advantages over prokaryotic expression systems . Moreover, compared to mammalian cell cultures, P. pastoris is more cost-effective and grows faster. Consequently, the majority of heterologous AMPs produced in yeast are expressed in P. pastoris .
The most commonly used vectors harbor the AOX promoter in P. pastoris, which is induced by methanol. Many AMPs have been expressed using this promoter, including hPAB-β , ABP-CM4  and Ch-penaeidin . Additionally, fungal defensin-plectasin and its derived peptides NZ2114, LHP7, and AgPlectasin have also been successfully expressed using this system in our laboratory with high production rates of 2390 mg/l, 906 mg/l, and 1285 mg/l, respectively [3,16,30,31]. However, methanol is a substance that is prone to cause fires during transportation and storage. The GAP promoter is an attractive alternative to the AOX promoter and might reduce costs and risks during the processes of fermentation and transportation. It has been shown that the various proteins, such as bacterial β-lactamase , D-amino acid oxidase and , human angiostatin , and functional mammalian membrane transport protein production , are more effectively expressed in constitutive systems than in the methanol-inducible system. In this work, all of the positive transformants exhibited some level of antimicrobial activity different levels (Figure 2A, B), However, the maximum total protein and rMP1102 yield were 43.6 mg/l and 18.31 mg/l after 72 h of cultivation (Figure 2C), which leaves much room for improvements via the optimization of fermentation.
Glyceraldehyde-3-phosphate dehydrogenase is the crucial enzyme in sugar metabolism. Consequently, the carbon source is one of the most important factors in the efficiency of the GAP promoter . The maximal transport activities of rPEPT2 growing on glucose are approximately 2 and 8 times greater than those on glycerol and methanol, respectively . Additionally, glucose at 40 g/l is the best choice for both cell growth and lipase production . However, glycerol is a better carbon source than glucose or methanol for the production of human angiostatin . It was also found that the methanol could also initiate the expression the reporter of β-lactamase, its activity was 36.36% compared to that of glucose as carbon source . Therefore, three carbon sources were tested at different concentrations in our work. The findings revealed that the maximum productions in terms of total protein, rMP1102 yield and antimicrobial activity were 67.8 mg/l, 27.8 mg/l and 6400 AU/ml following 96 h of cultivation at an initial glucose concentration of 40 g/l (Figure 3A, B).
Basal salt medium (BSM) and FM22 are the defined media commonly used in the large-scale production of heterologous proteins . The present work revealed that the maximum total protein level and rMP1102 yield in the defined medium were 100.06 mg/l and 42.83 mg/l, which was achieved using Med-1 (Figure 3C) at the shake flask level. Additionally, rich media might be more favorable than defined media for the production of some proteins. Yeast extract, peptone, and casamino acids are the complex media that are typically added to defined medium . These media can enhance the yield of target protein and protect host cells from proteolytic degradation. It has been shown that recombinant human consensus IFN-α (IFN-Con1) mutant can be highly expressed with a maximum yield of 1.23 g/l via the addition of yeast extract and peptone . Similarly, the highest yield of total protein, rMP1102 and antimicrobial activity of 280.41 mg/l, 120.57 and 12800 AU/ml was observed following the use of Med-1 supplemented with crude industrial yeast extract and peptone (Figure 4A, B). However, the yield of total protein, rMP1102 and antimicrobial activity reduced to 190.26 mg/l, 78.01 mg/l and 9600 AU/ml when Med-1 supplemented with Oxoid yeast extract and peptone was used (Figure 4A, B), which suggests that industrial media are more suitable for the high-level production of this target peptide. This difference might be due to the extensive machining processes that might keep the certain micronutrients in the industrial grade medium that improved target peptide yield. However, the exact mechanism will be studied in our future work. Moreover, the costs of industrial yeast extract and peptone were $ 9.68 and 11.29 per kilogram (Table 3), which were 3.17 and 7.57 times lower than the costs of the Oxoid components, respectively (Table 3); thus, the industrial yeast extract and peptone are likely more suitable for large-scale production.
Because P. pastoris grows in a wide range of pHs, the optimization of fermentation is typically adapted within these limits to provide the best conditions for individual proteins . The expression level of sEDIII-2 is highest at a pH of 5.8, and this level is 20–25% higher than those achieved at other pH values . Moreover, it has been found that an induction pH of 6.8 results in a merozoite surface protein 3 (MSP3) yield of at 434 mg/L, whereas this is no product at pH 5.0 despite though cell growth being identical across all pH levels . Consequently, pH values of 5.0 to 7.0 were selected for rMP1102 production at the 5-l fermenter level. The greatest amount of total protein, rMP1102 yield and antimicrobial activity were 1213.64 mg/l, 538.17 mg/l and 153,600 AU/ml in pH 6.5, with the highest productivity and specific cell growth rate of 285412 AU/mg rMP1102 and 0.224, respectively (Table 1), which corroborates the notion that, under the GAP promoter, the target peptide production was accompanied by the growth of host cells . Furthermore, this was the highest yield of antimicrobial peptide achieved using the GAP promoter and thus provides a practical system for the large-scale production of antimicrobial peptides with structures similar to that of MP1102.
For the first time, the novel NZ2114-derived peptide MP1102 was expressed in P. pastoris using the GAP promoter. Four percent initial glucose and Med-1 were identified as the best carbon source and medium, respectively, among three carbon sources and six media. Moreover, the replacement of Oxoid peptone and yeast extract (used in the research) with HRBS (crude industrial grade) was beneficial in terms of a higher yield of rMP1102. Additionally, the total protein level, rMP1102 yield, and antimicrobial activity increased from 807.42 mg/l, 367.59 mg/l, and 38,400 AU/ml, respectively, in pH 5.0 to the maximum values of 1213.64 mg/l, 538.17 mg/l and 153,600 AU/ml, respectively, at in pH 6.5. Together, the above results provide an economical strategy that is suitable the production of rMP1102 at the industrial level under the control of the GAP promoter in P. pastoris for the first time.
Strains, vectors, and reagents
Escherichia coli DH5α (Invitrogen, Beijing, China) was used as the host for plasmid maintenance and amplification. The pPICMP1102 plasmid was constructed and saved in our laboratory. The GAP gene was synthesized by Sangon Biotech (Shanghai, China). P. pastoris X-33 (Invitrogen, Beijing, China) was used for the expression. S. aureus ATCC 25923 was used in the antimicrobial activity assays. Restriction enzymes were purchased from New England Biolabs (NEB, Beijing, China). The kits for plasmid extraction and DNA purification were purchased from Tiangen (Beijing, China). All other chemical reagents were of analytical grade.
Construction of pGAPMP1102 and screening of the transformants
The pPICMP1102 recombinant plasmid was constructed in previous work . The AOX promoter of pPICMP1102 was replaced with the GAP promoter in this study, its detail including the restriction sites (Bgl II and Xho I) was shown in Figure 1. The target peptide was inserted in the downstream of the α-factor, which is most widely and successfully used secretion signal and can be self-cleaved by the Kex2 protease in P. pastoris, resulting in the native sequence of target protein. The recombinant plasmid was named pGAPMP1102 (GenBank accession number: KP636420) and transformed into E. coli DH5α. The positive transformants were screened by colony PCR and DNA sequencing. The correct positive plasmid was linearized with AvrII and transformed into P. pastoris X-33 by electroporation at 1,200 V charging voltage. The positive transformants were selected on YPDS plates (20 g/l peptone, 10 g/l yeast extract, 20 g/l glucose, 182.2 g/l sorbitol, and 20 g/l agar) containing 100 μg/ml Zeocin. The transformants were further confirmed by colony-PCR.
Expression of rMP1102 and optimization of cultivation in shaking flasks
The positive transformants were cultured overnight at 29°C and 250 rpm in 50-ml shaking flasks containing 10 ml YPD medium (20 g/l peptone, 10 g/l yeast extract, 20 g/l glucose). A 500-μl overnight culture was inoculated into a 250-ml shaking flask containing 50 ml YPD medium. Glucose (50%) was repeatedly added every 24 h to a final concentration of 0.5-1.0% (v/v) during the 72 h expression period, and the cell supernatants was collected every 24 h. The collected supernatants were centrifuged at 12,000 rpm for 10 min and stored at −20°C.
The colony with the highest expression level was selected and grown in 10 ml YPD medium overnight. This cell culture was further inoculated to an optical density (OD600) of 0.1-0.3 to initiate the cell growth and protein expression in the modified YP media (1% (w/v) yeast extract, 2% (w/v) peptone) supplemented with different carbon sources (i.e., glucose, glycerol, or methanol) at different concentration of 1, 2, 3, 4, and 5% (w/v). The culture supernatants were collected, and total protein levels were measured with a Bradford protein assay kit (Tiangen Biotech, Beijing, China). The yield of rMP1102 was calculated with Quantity One software, Version 4.6.2 (Bio-Rad, USA). The antimicrobial activity was assayed by the method described in the “Antimicrobial activity assays” section.
Based on the results of the carbon source screening, six different media (Table 4) were used to select the most suitable medium for large-scale production. In detail, a single colony of the recombinant strain was grown in 10 ml of YPD medium overnight and inoculated into 50 ml of YPD medium. The cell culture was further inoculated to an optical density (OD600) of 0.1-0.3 to initiate the cell growth and protein expression in 200 ml volumes of different media (Table 4). Glucose (50%) was repeatedly added every 24 h to a final concentration of 4.0% (v/v) during the 96 h expression period, and the cell supernatants were collected every 24 h. The total protein levels, rMP1102 yield and antimicrobial activities were tested. Tricine-SDS-PAGE was used to evaluate the expression levels of the target peptides. In this system, tricine is used instead of glycine in the cathode buffer due to that its stronger negative charge than glycine allows peptide to migrate faster. In addition, more ion movement and less protein movement from high ionic strength improves small proteins to be separated .
To further improve the rMP1102 yield, 2% peptone and 1% yeast extract from Oxoid (which are commonly used for research) and from Hongrun Baoshun (HRBS, these were crude and industrial grade) were added to Med-1, which was the medium that resulted in the maximum production of the target peptides. The methods for the cultivation, and total protein level and Tricine-SDS-PAGE assays were those described in the preceding paragraph.
Fed-batch fermentation at different pHs
The fermentation studies were conducted in 5-l bioreactors (BIOSTAT®B plus, Sartorius Stedim Biotech). A single colony was incubated in YPD medium at 30°C. An overnight culture was inoculated into 200 ml of fresh YPD medium and cultivated at 29°C (250 rpm) to an OD600 of 4–6. Next, 10% (v/v) inoculum was inoculated into a 5-L fermenter containing 2.0 L modified Med-1 medium (42.9 g/L KH2PO4, 14.3 g/l K2SO4, 11.7 g/l MgSO4 7H2O, 5 g/l (NH) 2SO4, 1.92 g/l citric acid anhydrous, 0.6 g/l CaSO4, 20.0 g/L yeast extract, 40.0 g/L peptone, 40.0 g/L glucose). The pH value was set to 6.0 at the glucose batch phase and changed to 5.0, 5.5, 6.0, 6.5, or 7.0 in the glucose fed-batch phase using NH4OH and H3PO4. The glucose feeding rate was 6 mL/L/h during the fed-batch culture phase. The dissolved oxygen (DO) level was maintained between 25 and 40% by adjusting the agitation, aeration, and rates. Foaming was controlled via the addition of antifoam. Cultivation broth samples were taken every 12 h for cell wet weight, extracellular protein level and antimicrobial activity analyses after centrifugation at 12,000 rpm for 10 min. The total protein levels, rMP1102 yield and antimicrobial activities were tested.
Purification and identification of rMP1102
The fermentation supernatant was dialyzed using a Sephadex G-25 column and lyophilized. The dried powder was dissolved in 20 mM of sodium phosphate buffer at a pH of 6.7 and loaded onto a HiTrap SP FF cation exchange chromatography (cIEX) column (length, 25 mm; internal diameter, 7 mm; GE Healthcare). First, 20-mM sodium phosphate buffer and 140-mM NaCl at a pH of 6.7 were used for elution, the concentration of NaCl was then increased to 600 mM, and the eluent of the corresponding elution peak was collected. Protein elution was monitored by measuring the UV absorbance at 215 and 280 nm.
The purified rMP1102 was analyzed by tricine-SDS-PAGE and confirmed by MALDI-TOF MS at the Laboratory of Proteomics, Institute of Biophysics, the Chinese Academy of Sciences according to previously reported methods . The purity of the target peptide was calculated with Quantity One software, version 4.6.2 (Bio-Rad, USA).
Antimicrobial activity assays
The tested strain of S. aureus ATCC 25923 was grown at 37°C to an OD600 of 0.4 in Mueller–Hinton (MH) medium (5 g/l beef infusion solids, 17.5 g/l casein hydrolysate, 1.5 g/l starch, and 3% serum, pH7.4). The cell suspension was inoculated into preheated MHA (5 g/l beef infusion solids, 17.5 g/l casein hydrolysate, 1.5 g/l starch, 20 g/l agar, 3% serum, pH 7.4). The medium was rapidly mixed and poured into a petri dish. Sterile oxford cups were placed on the surface of solidified the medium, and each cup was filled with 50-μl samples and incubated for 16–18 h at 37°C .
A titer assay was used to quantify the antimicrobial activity, which is expressed as arbitrary units (AU/ml). One arbitrary unit (AU) was defined as the reciprocal of the highest dilution that exhibited a clear zone of inhibition with the indicator strain. When a clear inhibition zone was followed by a turbid zone, the critical dilution was taken as the average of the final two dilutions .
All statistical analyses were performed using SPSS version 22.0. One-way analysis of variance (ANOVA) was used to determine the significance of the differences between groups. Differences were considered significant at P < 0.05.
Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389–95.
Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Sönksen CP, Ludvigsen S, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature. 2005;437:975–80.
Zhang J, Yang Y, Teng D, Tian Z, Wang S, Wang J. Expression of plectasin in Pichia pastoris and its characterization as a new antimicrobial peptide against Staphyloccocus and Streptococcus. Protein Exprs Purif. 2011;78:189–96.
Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science. 2010;328:1168–72.
Andes D, Craig W, Nielsen LA, Kristensen HH. In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrob Agents Chemother. 2009;53:3003–9.
Ostergaard C, Sandvang D, Frimodt-Moller N, Kristensen HH. High cerebrospinal fluid (CSF) penetration and potent bactericidal activity in CSF of NZ2114, a novel plectasin variant, during experimental pneumococcal meningitis. Antimicrob Agents Chemother. 2009;53:1581–5.
Brinch KS, Tulkens PM, Van Bambeke F, Frimodt-Moller N, Hoiby N, Kristensen HH. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. J Antimicrob Chemother. 2010;65:1720–4.
Xiong YQ, Hady WA, Deslandes A, Rey A, Fraisse L, Kristensen H-H, et al. Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:5325–30.
Waterham HR, Digan ME, Koutz PJ, Lair SV, Cregg JM. Isolation of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter. Gene. 1997;186:37–44.
Wang Q, Zhao LL, Sun JY, Liu JX, Weng XY. Enhancing catalytic activity of a hybrid xylanase through single substitution of Leu to Pro near the active site. World J Microbiol Biotechnol. 2012;28:929–35.
Khasa Y, Khushoo A, Srivastava L, Mukherjee K. Kinetic studies of constitutive human granulocyte-macrophage colony stimulating factor (hGM-CSF) expression in continuous culture of Pichia pastoris. Biotechnol Lett. 2007;29:1903–8.
Wu JM, Lin JC, Chieng LL, Lee CK, Hsu TA. Combined use of GAP and AOX1 promoter to enhance the expression of human granulocyte-macrophage colony-stimulating factor in Pichia pastoris. Enzyme Microb Technol. 2003;33:453–9.
Hong I-P, Lee S-J, Kim Y-S, Choi S-G. Recombinant expression of human cathelicidin (hCAP18/LL-37) in Pichia pastoris. Biotechnol Lett. 2006;29:73–8.
Hsu K-H, Pei C, Yeh J-Y, Shih C-H, Chung Y-C, Hung L-T, et al. Production of bioactive human α-defensin 5 in Pichia pastoris. J Gen Appl Microbiol. 2009;55:395–401.
Huang Y. Secretion and activity of antimicrobial peptide cecropin D expressed in Pichia pastoris. Exp Ther Med. 2012;4:1063–8.
Zhang Y, Teng D, Mao R, Wang X, Xi D, Hu X, et al. High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureus. Appl Microbiol Biotechnol. 2014;98:681–94.
Zhang AL, Luo JX, Zhang TY, Pan YW, Tan YH, Fu CY, et al. Recent advances on the GAP promoter derived expression system of Pichia pastoris. Mol Biol Rep. 2009;36:1611–9.
Weinhandl K, Winkler M, Glieder A, Camattari A. Carbon source dependent promoters in yeasts. Microb Cell Fact. 2014;13:5.
Tolner B, Smith L, Begent RHJ, Chester KA. Production of recombinant protein in Pichia pastoris by fermentation. Nat Protoc. 2006;1:1006–21.
Kozlov DG, Yagudin TA. Antibody fragments may be incorrectly processed in the yeast Pichia pastoris. Biotechnol Lett. 2008;30:1661–3.
Li YF, Chen ZX. RAPD: a database of recombinantly-produced antimicrobial peptides. FEMS Microbiol Lett. 2008;289:126–9.
Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3:238–50.
Feng XJ, Wang JH, Shan AS, Teng D, Yang YL, Yao Y, et al. Fusion expression of bovine lactoferricin in Escherichia coli. Protein Expr Purif. 2006;47:110–7.
Yang Y, Teng D, Zhang J, Tian Z, Wang S, Wang J. Characterization of recombinant plectasin: solubility, antimicrobial activity and factors that affect its activity. Process Biochem. 2011;46:1050–5.
Wang XJ, Wang XM, Teng D, Zhang Y, Mao RY, Wang JH. Recombinant production of the antimicrobial peptide NZ17074 in Pichia pastoris using SUMO3 as a fusion partner. Lett Appl Microbiol. 2014;59:71–8.
Cregg JM, Tolstorukov I, Kusari A, Sunga J, Madden K, Chappell T. Expression in the yeast Pichia pastoris. In: Burgess RR, Deutscher MP, editors. Guide to protein purification, vol. 463. 2nd ed. San Diego: Elsevier Academic Press Inc; 2009. p. 169–89 [Methods in Enzymology].
Chen Z, Wang D, Cong Y, Wang J, Zhu J, Yang J, et al. Recombinant antimicrobial peptide hPAB-β expressed in Pichia pastoris, a potential agent active against methicillin-resistant Staphylococcus aureus. Appl Microbiol Biotechnol. 2010;89:281–91.
Zhang J, Zhang SQ, Wu X, Chen YQ, Diao ZY. Expression and characterization of antimicrobial peptide ABP-CM4 in methylotrophic yeast Pichia pastoris. Process Biochem. 2006;41:251–6.
Li L, Wang JX, Zhao XF, Kang CJ, Liu N, Xiang JH, et al. High level expression, purification, and characterization of the shrimp antimicrobial peptide, Ch-penaeidin, in Pichia pastoris. Protein Expr Purif. 2005;39:144–51.
Mao R, Teng D, Wang X, Xi D, Zhang Y, Hu X, et al. Design, expression, and characterization of a novel targeted plectasin against methicillin-resistant Staphylococcus aureus. Appl Microbiol Biotechnol. 2013;97:3991–4002.
Xi D, Teng D, Wang X, Mao R, Yang Y, Xiang W, et al. Design, expression and characterization of the hybrid antimicrobial peptide LHP7, connected by a flexible linker, against Staphylococcus and Streptococcus. Process Biochem. 2013;48:453–61.
Zheng HB, Wang XL, Chen J, Zhu K, Zhao YH, Yang YL, et al. Expression, purification, and immobilization of His-tagged D-amino acid oxidase of Trigonopsis variabilis in Pichia pastoris. Appl Microbiol Biotechnol. 2006;70:683–9.
Zhang A, Zhang T, Luo J, Chen S, Guan W, Fu C, et al. Constitutive expression of human angiostatin in Pichia pastoris by high-density cell culture. J Ind Microbiol Biotechnol. 2007;34:117–22.
Doring F, Klapper M, Theis S, Daniel H. Use of the glyceraldehyde-3-phosphate dehydrogenase promoter for production of functional mammalian membrane transport proteins in the yeast Pichia pastoris. Biochem Biophys Res Commun. 1998;250:531–5.
Zhao W, Wang JW, Deng RQ, Wang XZ. Scale-up fermentation of recombinant Candida rugosa lipase expressed in Pichia pastoris using the GAP promoter. J Ind Microbiol Biotechnol. 2008;35:189–95.
Cregg JM. Pichia protocols. 2nd ed. Totowa: Humana Press Inc; 2007.
Wu D, Hao Y-Y, Chu J, Zhuang Y-P, Zhang S-L. Inhibition of degradation and aggregation of recombinant human consensus interferon-α mutant expressed in Pichia pastoris with complex medium in bioreactor. Appl Microbiol Biotechnol. 2008;80:1063–71.
Batra G, Gurramkonda C, Nemani SK, Jain SK, Swaminathan S, Khanna N. Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris. J Biosci Bioeng. 2010;110:408–14.
Wang J, Nguyen V, Glen J, Henderson B, Saul A, Miller LH. Improved yield of recombinant merozoite surface protein 3 (MSP3) from Pichia pastoris using chemically defined media. Biotechnol Bioeng. 2005;90:838–47.
Zhang Y, Teng D, Wang X, Mao R, Cao X, Hu X, et al. In vitro and in vivo characterization of a new recombinant antimicrobial peptide, MP1102, against methicillin-resistant Staphylococcus aureus. Appl Microbiol Biot. 2015;99:1–12. doi:10.1007/s00253-015-6394-7.
Schägger H. Tricine–SDS-PAGE. Nat Protoc. 2006;1:16–22.
Liu L, O’Conner P, Cotter P, Hill C, Ross R. Controlling Listeria monocytogenes in cottage cheese through heterologous production of enterocin A by Lactococcus lactis. J Appl Microbiol. 2008;104:1059–66.
Schilling BM, Goodrick JC, Wan NC. Scale-up of a high cell density continuous culture with Pichia pastoris X-33 for the constitutive expression of rh-Chitinase. Biotechnol Prog. 2001;17:629–33.
Tian ZG, Dong TT, Yang YL, Teng D, Wang JH. Expression of antimicrobial peptide LH multimers in Escherichia coli C43 (DE3). Appl Microbiol Biot. 2009;83:143–9.
The authors gratefully thank Prof. Yang Fuquan (The Proteomics Platform Laboratory at the Institute of Biophysics, Chinese Academy of Sciences) for his coordination of the MALDI-TOF MS analysis. This study was supported by the National Natural Science Foundation of China (No. 31372346 and No. 31302004), the Project of the National Support Program for Science and Technology in China (No. 2013BAD10B02 and No. 2011BAD26B02), the Postdoctoral Science Foundation in China (No. 2014 M550906), the Special Fund for Agro-scientific Research in the Public Interest in China (No. 201403047), and the AMP Direction of National Innovation Program of Agricultural Science and Technology in CAAS (CAAS-ASTIP-2013-FRI-02).
The authors declare that they have no competing interests.
RM performed the codon optimization, vector construction, and expression and purification of MP1102. YZ performed the design of MP1102 and partial optimization at the fermenter level. DT and XW coordinated the project. JJ and XC screened the carbon sources and media. JW provided critical advice on all designs and results. RM and JW wrote this paper. All authors have read and approved the final manuscript.
About this article
Cite this article
Mao, R., Teng, D., Wang, X. et al. Optimization of expression conditions for a novel NZ2114-derived antimicrobial peptide-MP1102 under the control of the GAP promoter in Pichia pastoris X-33. BMC Microbiol 15, 57 (2015). https://doi.org/10.1186/s12866-015-0389-5
- GAP promoter
- Pichia pastoris